Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;31(2):277-282.
doi: 10.1080/14397595.2020.1830512. Epub 2020 Oct 12.

Non-radiographic axial spondyloarthritis

Hideto Kameda  1 , Shigeto Kobayashi  2 , Naoto Tamura  3 , Yuho Kadono  4 , Kurisu Tada  3 , Masahiro Yamamura  5 , Tetsuya Tomita  6
Affiliations
Free article
Review

Non-radiographic axial spondyloarthritis

Hideto Kameda et al. Mod Rheumatol. 2021 Mar.
Free article

Abstract

Non-radiographic axial spondyloarthritis (nr-axSpA) is a subgroup of axial spondyloarthritis (axSpA) without fulfilling the modified New York criteria of sacroiliac joint radiographs for ankylosing spondylitis (AS). AS and nr-axSpA share various demographic and clinical features and disease burden, although sex and objective inflammatory findings such as elevated serum C-reactive protein level are slightly different between AS and nr-axSpA. Recently, diagnostic guidance for nr-axSpA in Japan was proposed for epidemiological studies of a population with a low prevalence of HLA-B27 positivity and the use of molecular targeted agents suitable for the unique medical care system in Japan. A biological agent targeting interleukin-17 was approved for nr-axSpA by the Pharmaceutical and Medical Devices Agency (PMDA) in August 2020. Some other biological agents will be also available for Japanese patients with nr-axSpA in the near future.

Keywords: Axial spondyloarthritis; HLA-B27; diagnosis; inflammatory back pain; sacroiliitis.

PubMed Disclaimer

MeSH terms